Scendea’s Post

Attention--Japanese leading clinical #CRO A2 Healthcare has launched its Boston office to help accelerate the rapid expansion of its US Pipeline Accelerator Program (#PAP). The company is offering financial #incentives – both contract services and project financing – for select US #biotech pipelines to support their clinical-stage development, particularly for entering the Japan and Taiwan markets where 72 percent of drugs approved in Europe and the United States were not approved in 2020. A2 Healthcare's PAP can be a game changer for global biotech companies that are responsible for more than half of the domestically unapproved drugs in #Japan. 

It’s fascinating to see the difference a strategic partnership can make in a drug development program. Check out our white paper to discover how a multidisciplinary collaboration can benefit your drug development program: https://bit.ly/4cqNm68 https://bit.ly/3LTkKah

Thoughts on this? >> A CAR-T deal in China; Zevra’s $60M offering >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #productmarketing #pharma #pharmaceutical

Thoughts on this? >> BeiGene looks beyond China as it secures new API source, nears opening of US site >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #healthcare #pharmaceutical #biotech

The European Commission published a report from the COMBINE project mapping  the combined studies landscape, which includes the following aspects: ➡ Issues and challenges facing combined studies ➡ Practices of  Member States’ competent authorities ➡ Estimations of performance study submissions ➡ Average time from submission to approval ➡ Existing work and literature on combined studies ➡ Solutions to challenges and future work directions/items The next steps will involve Member States’ expert groups, the EU Commission, and relevant stakeholders. https://bit.ly/4dM5oAO #Pharma #Medtech #EU #CombinedProducts  

EXCERPTS: Few life sciences companies have taken steps to cut ties with firms named in proposed US legislation aimed at cutting reliance on China’s drug supply chain, a survey showed, underscoring lingering uncertainty around the bill. Although 26% of companies are looking to disconnect from those named — including BGI, MGI Tech, WuXi AppTec Co. and related entities — a poll conducted by Boston-based L.E.K. Consulting in June found only 2% of life sciences companies have severed ties, and 11% reported no impact on their partnership decisions. The lack of action in response to the planned legislation reflects the importance of the Chinese companies, which also include WuXi Biologics Cayman Inc., in the global pharma supply chain.

Thoughts on this? >> BeiGene looks beyond China as it secures new API source, nears opening of US site >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #healthcare #pharma #pharmaceutical

The first investment refers to INDUSTRY 5.0 approved by the European Commission. Company #Vonpharma Si, predstavništvo in prodaja, d. o. o. Location #SLOVENIA Amount EUR 5,870,871.27. The company and the products or services are in no relation to INDUSTRY 5.0 origin or principles. Details zn the next INDUSTRY 5.0 NEWSLETTER INDUSTRY 5.0 AMBASSADORS NETWORK Industry 5.0 INDUSTRY 5.0 STRATEGIC ALLIANCE

This workshop will focus on common issues seen in abbreviated new drug applications (ANDAs), GDUFA III updates, GDUFA science and research on complex products and scientific issues to product-specific guidance development, pre-ANDA, and ANDA meeting discussions, and examine various areas of innovative science and cutting-edge methodologies behind generic drug development.

It’s fascinating to see the difference a strategic partnership can make in a drug development program. Check out our white paper to discover how a multidisciplinary collaboration can benefit your drug development program: https://bit.ly/4cqNm68 https://bit.ly/4cQlR6n